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Abstract. Endoscopic ultrasound‑guided fine‑needle aspira-
tion (EUF-FNA) has improved the diagnosis of pancreatic 
lesions. Next-generation sequencing (NGS) facilitates the 
production of millions of sequences concurrently. Therefore, 
in the current study, to improve the detectability of oncogenic 
mutations in pancreatic lesions, an NGS system was used 
to diagnose EUS-FNA samples. A total of 38 patients with 
clinically diagnosed EUS-FNA specimens were analyzed; 
27 patients had pancreatic ductal adenocarcinoma (PDAC) 
and 11 had non-PDAC lesions. DNA samples were isolated and 
sequenced by NGS using an Ion Personal Genome Machine 
system. The Cancer Hotspot Panel v2, which includes 
50 cancer-related genes and 2,790 COSMIC mutations, was 
used. A >2% mutation frequency was defined as positive. 
KRAS mutations were detected in 26 of 27 PDAC aspirates 
(96%) and 0 of 11 non-PDAC lesions (0%). The G12, G13, and 
Q61 KRAS mutations were found in 25, 0, and 1 of the 27 
PDAC samples, respectively. Mutations were confirmed by 
TaqMan® polymerase chain reaction analysis. TP53 mutations 
were detected in 12 of 27 PDAC aspirates (44%). SMAD4 
was observed in 3 PDAC lesions and cyclin-dependent kinase 
inhibitor 2A in 4 PDAC lesions. Therefore, the current study 
was successfully able to develop an NGS assay with high 
clinical sensitivity for EUS-FNA samples.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is a leading cause 
of cancer-associated mortality in the United States and Japan, 
and its incidence continues to increase (1,2). PDAC has one 
of the lowest survival rates, with a 5-year survival rate of 
<10% (1,2). Therefore, improved methods of diagnosing PDAC 
are required.
A number of diagnostic modalities for PDAC have been 
developed. Among them, endoscopic ultrasound-guided 
fine‑needle aspiration (EUS‑FNA) has become an important 
method of diagnosing pancreatic tumors due to its high safety, 
cost-effectiveness and accuracy (3,4). EUS-FNA demonstrates 
high sensitivity for histological diagnosis (75-94%) and a 
specificity approaching 100% in the majority of studies (5,6). 
However, false-negative, atypical and suspicious cytopatho-
logical diagnoses remain relatively frequent (5,7,8).
Activating mutations in the KRAS gene are observed in 
>95% of patients with PDAC and may be one of the earliest 
steps in the formation of pancreatic intraepithelial neoplasia 
(PanIN) (9-11). Molecular profiling studies have demonstrated 
that PanIN-to-PDAC progression occurs by inactivation of the 
tumor suppressor genes tumor protein 53 (TP53), cyclin-depen-
dent kinase inhibitor 2A (CDKN2A) and/or SMAD4 (12-15). 
With a few rare exceptions, the genetic mutations in patients 
with cancer that activate KRAS proteins predominantly result 
from one of three single point mutations at residues G12 (98%), 
G13 (<1%) or Q61 (<1%) (9).
Mutation profiling has been attempted using traditional 
single-gene analysis, which is commonly performed with 
Sanger sequencing. However this is costly, relatively low 
in sensitivity, and time- and labor-intensive. Furthermore, 
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substantial amounts of DNA are required; thus the simulta-
neous evaluation of several genes within a small specimen is 
not possible. Next-generation sequencing (NGS) solves this 
problem due to its ability to perform multiplex, high-throughput 
sequencing of many samples for multiple genes. NGS allows 
druggable mutations to be identified and a more complete 
genotype of a given type of cancer to be generated. The use 
of NGS and the combined analysis of separate sets of data 
thus enable a more detailed picture of a specific disease to be 
established (7,16).
A number of studies have assessed the genetic changes 
in resected PDAC specimens by NGS (15,17). However, the 
majority of PDACs are inoperable due to disease progression. 
To overcome this issue, the use of specimens obtained by 
EUS-FNA is preferable and promising for clinical application.
The aim of the current study therefore, was to establish 
an NGS assay for genetic alterations in pancreatic specimens 
obtained via EUS-FNA.
Materials and methods
Patients. A total of 38 patients with pancreatic disease were 
eligible for the current study, and underwent EUS-FNA at 
the Gastroenterological Center, Yokohama City University 
Medical Center (Yokohama, Japan) between September 2013 
and March 2015. Eligible patients were pathologically or 
clinically diagnosed as having pancreatic disease and provided 
written informed consent to participate in the current study. 
None of the patients had previously undergone chemotherapy 
or radiotherapy. Out of all the patients, 27 were diagnosed 
with PDAC and 11 with non-PDAC lesions. Non-PDAC lesions 
included autoimmune pancreatitis (AIP), intraductal papillary 
mucinous neoplasms (IPMN), serious cystic neoplasms (SCN), 
pancreatic neuroendocrine tumors (NETs) and tumor-forming 
chronic pancreatitis (CP) (Table I). There were 26 male and 
12 female patients with an average age of 66.5 years (range, 
39-86 years). EUS-FNA was performed using a linear echo-
endoscope and the aspirated material was smeared onto 
microscope slides for on-site examination. Hematoxylin and 
eosin staining was performed and a pathologist reviewed the 
slides. A portion of the tissues was stored at ‑80˚C until DNA 
extraction. The study protocol was approved by the Ethics 
Committee at Yokohama City University.
DNA extraction and library preparation. DNA from direct 
EUS-FNA material was extracted using a ReliaPrep™ gDNA 
Tissue Miniprep system (Promega Corporation, Madison, 
WI, USA), according to the manufacturer's instructions. The 
highly intact and nondegraded RNA-free genomic DNA was 
subjected to library preparation prior to sequencing.
Multiplex polymerase chain reaction (PCR) was 
performed by amplifying 10 ng of DNA using the Ion 
AmpliSeq™ Cancer Hotspot Panel v2.0 and the Ion 
AmpliSeq™ Library kit v2.0 (Thermo Fisher Scientific, 
Inc., Waltham, MA, USA). Somatic mutations (substitu-
tions, insertions, or deletions) were designed to amplify 
207 amplicons covering ~2790 Catalogue of Somatic Muta-
tions in Cancer (COSMIC) mutations from the 50 most 
commonly reported oncogenes and tumor suppressor genes 
(Ion Torrent™; Thermo Fisher Scientific, Inc.). Sequencing 
library preparation was performed according to the manu-
facturer's instructions (18,19).
Emulsion PCR and Ion Torrent personal genome machine 
(PGM)™ sequencing. Pooled, barcoded libraries were clonally 
amplified using the Ion OneTouch™ 2 instrument from the Ion 
PGM™ Template OT2 200 kit (Thermo Fisher Scientific, Inc.) 
according to the manufacturer's instructions (20). Ion sphere 
particles were enriched using the Ion One Touch™ enrich-
ment system (Thermo Fisher Scientific, Inc). The subsequently 
enriched template-positive ion sphere particles were loaded 
onto an Ion 316™ chip and sequenced on the PGM using the 
Ion PGM sequencing 200 kit v2 (Thermo Fisher Scientific, 
Inc.). Data from sequencing runs on the Ion Torrent PGM™ 
were automatically transferred to the Torrent Server hosting 
the Torrent Suite™ Software v4.4.3 (Thermo Fisher Scientific, 
Inc.). The Torrent Suite Software uses the Torrent Browser, 
which includes the Torrent Mapping Alignment Program and 
Torrent Variant Caller for alignment and variant detection. 
A human genome reference sequence (hg19) was used as a 
reference. Ion Reporter™ Software (Thermo Fisher Scientific, 
Inc.) was used to perform variant calling and mapping. A >2% 
mutation frequency was defined as positive.
TaqMan® PCR. TaqMan® Mutation Detection assays (Thermo 
Fisher Scientific, Inc.) were used to confirm the KRAS 
codon-12 mutations (c.34 G>Cp.pG12R, c.35 G>A p.12D, 
c.35 G>T p.G12 V) revealed by NGS analysis. Briefly, detec-
tion experiments were performed using reaction mixtures 
comprising a DNA template, one Genotyping Master Mix and 
one TaqMan® Detection assay containing an allele‑specific 
forward primer, locus‑specific reverse primer, allele‑specific 
blocker and locus‑specific TaqMan® probe. Quantitative PCR 
(qPCR) was performed on an Applied Biosystems® 7,500 fast 
real-time PCR system (Applied Biosystems; Thermo Fisher 
Scientific, Inc.). A >0.1% mutation frequency was defined as 
positive.
Results
Clinicopathological characteristics. Final diagnoses of 
solid pancreatic lesions based on EUS-FNA following 
cytopathology and clinical passage are presented in Table I. 
Of the 38 patients, 27 had PDAC (19 males, 8 females) and 
mean patient age was 66.5 years (range, 39-86 years). Histo-
logical analysis of EUS-FNA samples indicated that 19 of the 
27 PDAC samples were diagnosed with adenocarcinoma and 
1 sample was diagnosed as suspicious for adenocarcinoma. Of 
the remaining samples, 6 were diagnosed as atypical epithe-
lium and 1 sample was diagnosed as exhibiting no malignancy 
(Table II).
The mean size of the PDAC tumors at the greatest diameter 
was 36.8 mm (range, 16-64 mm). Of all PDAC lesions, 12 were 
located in the pancreatic head, 7 were in the pancreatic body to 
tail, 6 were in the pancreatic body and 2 were in the pancreatic 
tail. (Table II). According to the UICC (Union International 
Cancer Control) clinical staging system, 16 PDACs were 
stage IV, 7 were stage III, 3 were stage IIA, and 1 was stage IA 
(Table II). The diagnoses of the 11 patients who did not have 
PDAC were as follows: 2 cases of metastatic cancer, 2 cases 
ONCOLOGY LETTERS  12:  3875-3881,  2016 3877
of NET, 1 case of IPMN, 1 case of SCN, 3 cases of AIP and 
2 cases of CP (Table III).
Prevalence of gene mutations in EUS‑FNA samples by NGS. 
Using the Ion Ampliseq™ Cancer Hotspot Panel v2 (Thermo 
Fisher Scientific, Inc.), which includes the 50 most common 
cancer-related genes and 2,790 COSMIC mutations, 10 ng of 
DNA was analyzed according to the manufacturer's protocol. 
The average sample loading obtained was 67% (range, 46-91%) 
and the average number of total reads was 481,049 with an 
average read length of 105 bp.
Following the analysis, putative germline mutations and 
nonsignificant mutations, including synonymous ones, were 
excluded. Among the 27 PDACs, 26 tumors (96%) had KRAS 
mutations; of these, 15 had G12D (c.35 G>A), 6 had G12 V 
(c.35 G>T), 3 had G12R (c.34 G>C), 1 had G12C (c.34 G>T) 
and 1 had Q61H (c.183 A>T) mutations. TP53 mutations 
were detected in 12 of the 27 samples (44%). The details 
of the TP53 mutations are presented in Table IV. These 
mutations were evaluated by TransFIC (TRANSformed 
Functional Impact for Cancer) (21) and their level of impact 
was assessed; those determined to have a high impact are 
presented (Table IV). SMAD4 and CDKN2A mutations were 
identified in 3 of 27 samples (11%; #2: c.1487G>A, #10: 
c.1558G>T, #19: c.984C>G) and 4 of 27 samples (15%; #7: 
c.152T>A, #12: c.242C>T, #16:c.197A>G, #26:c.238C>T), 
respectively (Table II). MET (#26:c1124A>G) and KIT 
(#26:c.1621A>C) mutations were each identified in 1 sample 
(3.7%; Table II). In the remaining 9 samples, 1 sample from 
metastatic carcinoma exhibited VHL, BRAF and GNAS 
mutations, suggesting that the tumor was not derived from 
the pancreas but from another organ, such as the colon or 
kidney (Table III). One sample from a metastatic pancreatic 
tumor harbored the TP53 mutation, however the primary 
locus could not be determined. The remaining 9 samples 
exhibited no putative driver mutation (Table III).
Validation analysis of KRAS mutation by TaqMan® assay. A 
TaqMan® gene expression PCR assay was used to validate the 
KRAS mutations detected by NGS (17,22,23). PCR primers 
were only used for the G12 V, G12D and G12R, and all muta-
tions detected by NGS were also detected by the TaqMan® 
assay. However, neither NGS nor the TaqMan assay was able 
to detect a KRAS mutation in 1 PDAC sample (sample ID 
15; Table II). Mutations of Q61H or G12C detected by NGS 
(sample ID 18 or 27; Table II) had not been determined. The 
G12D mutation was detected in a sample from a patient with 
AIP. However, the TaqMan assay is able to detect mutations 
with a frequency of <0.1%, whereas the mutation frequency 
must be >2% to be defined as positive by NGS.
Discussion
In the current study, an NGS mutational analysis system was 
established for EUS-FNA tissue samples. The diagnostic 
accuracy of EUS-FNA by histological analysis is sometimes 
insufficient. Associated factors include the size of the tissue 
sample, size or location of the tumor, and operator's tech-
nique (7,16,24). The current study revealed that 7 of 27 PDAC 
samples were not diagnosed as adenocarcinoma by histological 
analysis; furthermore, PNAC diagnosis may differ according 
to the pathologist involved. For example, in the current study, 
2 PDAC patients (sample IDs 21 and 22; Table II) were not 
diagnosed as adenocarcinoma by pathological analysis in 
EUS-FNA samples and therefore underwent surgical biopsy. 
A method for objective and accurate diagnosis of EUS‑FNA 
samples should be established, which would result in more 
widespread use of the EUS-FNA technique. The present study 
has demonstrated that NGS and TaqMan analysis are able to 
detect KRAS mutations in EUS-FNA samples. If detection of 
KRAS mutations is established as a method of PDAC diag-
nosis, the rate of successful PDAC diagnosis may improve and 
patients may receive effective treatment more promptly.
In general, pancreatic tumor tissue contains fibroblasts or 
hematopoietic cells and in some cases, may even contain more 
fibroblasts than tumor cells (25). Therefore, the use of Sanger 
sequencing for PDAC is difficult due to possible contamination 
by fibroblasts. It has been demonstrated that detecting KRAS 
mutations, the most common and important mutations for the 
development of PDAC, by a qPCR-based method is accurate 
and highly sensitive (26). However, mutational analysis of 
other PDAC driver genes including TP53, is relatively difficult. 
Additionally, these genetic mutations may provide information 
to aid the diagnosis of PDAC, furthermore, certain muta-
tions including TP53 and SMAD4, are predictive of a poorer 
prognosis of patients with PDAC (27,28). However, TP53 or 
SMAD4 mutations have been found in several exons; thus, 
Sanger sequencing of many loci or analysis at the protein level 
is necessary. NGS may overcome these problems; indeed, 
the present study demonstrated that the TP53 mutation locus 
differed among the patients assessed. In addition, it is difficult 
to perform a protein analysis using EUS-FNA samples due to 
the low quantity of protein they contain.
There has been a recent focus on personalizing PDAC 
treatment by analyzing genetic alterations or molecular 
biomarkers. Despite intensive research, personalized therapy 
for patients with PDAC has not yet been established. Erlotinib 
is an important drug approved for the treatment of PDAC 
and is very effective. However, no biomarker for its use has 
been established. A previous in vivo study has suggested that 
epidermal growth factor signaling, the target of erlotinib, is 
more active in the presence of the TP53 mutation (29); there-
fore, erlotinib may not be effective in patients with PDAC 
Table I. Final clinical diagnosis of pancreatic lesions reference 
for EUS guided FNA.
Final diagnosis No. of lesions
Pancreatic adenocarcinoma  27
Metastatic pancreatic tumor   2
Neuroendocrine tumor    2
Intraductal papillary mucinous neoplasm    1
Serous cystic neoplasm     1
Autoimmune pancreatitis    3
Chronic pancreatitis    2
Total 38
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exhibiting TP53 mutations. Future studies should clarify 
whether the TP53 mutation may be used as a biomarker for the 
administration of erlotinib.
The EUS-FNA technique is used worldwide and is consid-
ered to be the most powerful method for the histological 
diagnosis of pancreatic tumors. PDAC has a markedly unfavor-
able prognosis; the 5-year survival rate is <10% and the disease 
is usually diagnosed at an advanced, inoperable stage (1,2). 
Therefore, EUS-FNA is the sole method of obtaining tumor 
tissue in the majority of patients with advanced‑stage disease. 
A method for the diagnosis and determination of the appro-
priate therapy using EUS-FNA samples is required.
Such a method is also important for the diagnosis of other 
pancreatic masses, including metastatic tumors, lymphoma, 
IPMC, NET and benign lesions. In the current study, 11 samples 
from patients with other pancreatic masses (non-PDAC) were 
analyzed. As described above, >95% of PDACs exhibit the 
KRAS mutation; therefore, its absence reduces the probability 
of PDAC diagnosis. This information may facilitate the 
differential diagnosis of a malignancy and a benign disorder. 
Table IV. TP53 mutations identified in PDAC patients.
Sample ID Mutation  Protein change Type transFIC prediction
  1 g.chr17:7578553 p.T126S SNP Driver mutation
  2 g.chr17:7577141 p.G266V SNP Driver mutation
  3 g.chr17:7577120 p.R273C SNP Driver mutation
  4 g.chr17:7578406 p.A175H SNP Driver mutation
  5 g.chr17:7577547 p.G245N SNP Driver mutation
  6 g.chr17:7579388 p.G1100Ter SNP Strongly affecting mutation
  7 g.chr17:7577553 p.C242S SNP Strongly affecting mutation
  7 g.chr17:7578434 p.S166A SNP Strongly affecting mutation
  8 g.chr17:7577570 p.M237I SNP Driver mutation
10 g.chr17:7577103 p.R280fs INDEL Putative affecting
17 g.chr17:7577559 p.S241F SNP Driver mutation
24 g.chr17:7578448 p.A161N SNP Strongly affecting mutation
25 g.chr17:7578201 p.H214A SNP Strongly affecting mutation
PDAC, pancreatic ductal adenocarcinoma; SNP, single nucleotide polymorphisms; INDEL, small insertions and deletions; transFIC, 
TRANSformed functional impact for cancer.
Table III. Clinicopathological features and details of genetic mutations in non-PDAC patients.
      Amino  
     KRAS acid TP53 
Sample Final    mutation substitution mutation Other
ID diagnosis Age Gender Histology  (NGS) (TaqMan) (NGS) mutations
28 Metastatic pancreatic cancer 45 F No malignancy - - + 
29 Metastatic pancreatic cancer 86 F Adenocarcinoma - - - BRAF, VHL, GNAS
30 NET 55 M NET - - - 
31 NET 46 M No malignancy - - - 
32 IPMN 64 F No malignancy - - - 
33 SCN 68 M No malignancy - - - 
34 AIP 77 M No malignancy - - - 
35 AIP 71 F No malignancy - G12D - 
36 AIP 67 M No malignancy - - - 
37 CP 52 M No malignancy - - - 
38 CP 47 M No malignancy - - - 
M, male; F, female; AIP, autoimmune pancreatitis; CP, chronic pancreatitis; EUS‑FNA, endoscopic ultrasound‑guided fine‑needle aspiration; 
IPMN, intraductal papillary mucinous neoplasm; NET, neuroendocrine tumors; NGS, next generation sequencing; PDAC, pancreatic ductal 
adenocarcinoma; SCN, serous cystic neoplasm; TP53, tumor protein 53; BRAF, proto-oncogene B-RAF; VHL, von Hippel-Lindau tumor 
suppressor; GNAS, GNAS complex locus.
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Accurately diagnosing solid pancreatic tumors is critical to 
avoid chemotherapy or unnecessary resections in patients with 
benign lesions, including AIP and focal lesions of CP.
Differential diagnosis between PDAC and other malignan-
cies is sometimes difficult. In the current study, samples from 
metastatic tumors of unknown origin were used. One sample 
harbored BRAF and VHL mutations but no KRAS mutations, 
suggesting that the tumor was unlikely to be PDAC and may 
have been metastatic pancreatic cancer. However, KRAS muta-
tions have been detected in other types of cancer, including 
those of the lung, colon and stomach (30). Determinating the 
tumor origin by genetic analysis alone is difficult in such cases.
The present study had several limitations, the most promi-
nent of which was the relatively small sample size. However, 
the study did establish genetic mutational analysis by NGS 
with EUS-FNA samples. In addition, the Ampliseq cancer 
panel was used to analyze 50 genes containing 1650 hotspots. 
This may not be sufficient to profile the landscape of PDAC. 
Following the establishment of genetic diagnosis-based 
treatment methods, even more accurate methods of genetic 
diagnosis should be established.
The current study eliminated the results of suspected 
germline mutations. However, determining whether a muta-
tion is germ line or somatic is difficult, and both tumor 
samples and normal tissue control samples must therefore be 
used. Furthermore, the mutation should be identified as either 
driver or passenger to determine whether mutational analysis 
is clinically appropriate.
In conclusion, an NGS assay of EUS-FNA samples was 
successfully established in the present study. Analysis of 
oncogenic mutations using NGS enabled very high clinical 
sensitivity. The assay developed herein may be incorporated 
into clinical laboratories as a routine test for diagnosing and 
constructing personalized therapy for patients with PDAC.
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